Hepatitis B drug „Tifentai“ enters clonical research

The drug, developed by Professor Guangyi LIANG of CAS Key Laboratory of Chemistry for Natural Products in Guizhou, is based on chemically synthesized key components of hepatitis B virus which are easy to produce, and has been shown in preclinical studies to be efficient, have a unique site of action and does not lead to resistance.

Chine Bio news release, August 22, 2014

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year. Accept or Deny